Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:06:02 EDT Sat 05 Jul 2025
Enter Symbol
or Name
USA
CA



Q:CADL - CANDEL THERAPEUTICS INC - https://ir.candeltx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CADL - Q1.25.05·5.140.15.10+0.112.2619.14.95  5.12  4.8914.60  3.785Jul 03Jun 2415 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-24 09:06U:CADLNews ReleaseCandel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
2025-06-23 08:05U:CADLNews ReleaseCandel Therapeutics Appoints Charles Schoch as Chief Financial Officer
2025-06-06 08:05U:CADLNews ReleaseCandel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
2025-05-28 08:05U:CADLNews ReleaseCandel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
2025-05-27 08:05U:CADLNews ReleaseCandel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
2025-05-22 17:05U:CADLNews ReleaseCandel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
2025-05-13 08:05U:CADLNews ReleaseCandel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
2025-05-06 08:05U:CADLNews ReleaseCandel Therapeutics to Present at Upcoming Investor Conferences
2025-04-23 16:05U:CADLNews ReleaseCandel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
2025-04-01 08:01U:CADLNews ReleaseCandel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
2025-03-26 16:05U:CADLNews ReleaseCandel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
2025-03-20 08:00U:CADLNews ReleaseCandel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
2025-03-18 08:01U:CADLNews ReleaseCandel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
2025-03-13 16:15U:CADLNews ReleaseCandel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
2025-02-25 08:00U:CADLNews ReleaseCandel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
2025-01-13 08:00U:CADLNews ReleaseCandel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
2024-12-16 16:01U:CADLNews ReleaseCandel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
2024-12-12 23:01U:CADLNews ReleaseCandel Therapeutics Announces Pricing of Public Offering
2024-12-12 16:51U:CADLNews ReleaseCandel Therapeutics Announces $80 Million Proposed Public Offering
2024-12-11 07:00U:CADLNews ReleaseCandel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival